

Updates in the Diagnosis and Management of Chronic Active Antibody Mediated Rejection

Supported by CSL Behring

Increasingly recognized, chronic active antibody mediated rejection (CAMR) is a common post-transplant complication that reduces kidney transplant allograft longevity. In this session, thought leaders and researchers in the field will provide attendees with an overview of chronic active antibody mediated rejection and its impacts on allograft survival as well as exciting updates on new diagnostics as well as treatment strategies to address it. The moderators, at the end of each talk, will then introduce questions that will facilitate additional debate and discussion that will serve to examine each topic in more detail.